Lab Views Newsletter July 2008
ACT's eNewsletter, Lab Views, brings you news specific to the laboratory and its uses in clinical trials including deals, alliances, business developments, people news, and events.
FDA Advisory Committee on Cardiovascular Safety
The FDA Endocrinology and Metabolic Drugs Advisory Committee recently voted to recommend that the FDA require pharma companies to establish cardiovascular safety evidence for new diabetes medicines. How will this impact the clinical trials industry? Joel Morganroth, MD, Chief Scientist at eResearch Technology, told Applied Clinical Trials that in the area of cardiovascular testing, "A core ECG laboratory can provide consistent and accurate evaluation of changes from baseline in 12-lead ECG morphology (such as new myocardial infarction pattern) plus identification of interval changes (e.g. QT prolongation and risk for sudden death from an arrhythmia) signals of which may be lost or be falsely positive using site interpreted ECGs. Site interpreted ECG data has so much variability and inaccuracies that core laboratory analysis, like other critical research endpoints, should always be employed."
»
WorldCare Clinical
Providing imaging clinical trial services with the industry’s most efficient technology platform and leading operational and therapeutic expertise.
-
August 4, 2008
The Westin Hotel|Philadelphia, PA
September 10-11, 2008
Courtyard Marriott Brussels|Belgium
October 21-22, 2008
World Trade Center|Boston, MA
- IBT Laboratories' new president and COO.
- ACR Image Metrix adds clinical research project manager.
- MDS Pharma Services' Vice President of Scientific Affairs for its global central labs network.
Sally Warner, Medical Director, Medical Imaging Group for Perceptive Informatics, discusses "The Role of Labs in Imaging Components for Diabetes Trials" in our podcast series titled Challenges & Solutions in Diabetes.
You are subscribed to %%list.name%% as %%emailaddr%%. To unsubscribe from this list
To ensure delivery to your Inbox, please add %%email.list%% to your address book. If you need help doing this,
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025